2D1X

The crystal structure of the cortactin-SH3 domain and AMAP1-peptide complex


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.9 Å
  • R-Value Free: 0.226 
  • R-Value Work: 0.216 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Targeting AMAP1 and cortactin binding bearing an atypical src homology 3/proline interface for prevention of breast cancer invasion and metastasis.

Hashimoto, S.Hirose, M.Hashimoto, A.Morishige, M.Yamada, A.Hosaka, H.Akagi, K.Ogawa, E.Oneyama, C.Agatsuma, T.Okada, M.Kobayashi, H.Wada, H.Nakano, H.Ikegami, T.Nakagawa, A.Sabe, H.

(2006) Proc.Natl.Acad.Sci.Usa 103: 7036-7041

  • DOI: 10.1073/pnas.0509166103

  • PubMed Abstract: 
  • Invasive potentials of carcinomas greatly contribute to their metastasis, which is a major threat in most cancers. We have recently shown that Arf6 plays a pivotal role in breast cancer invasive activities and identified AMAP1 as an effector of GTP-A ...

    Invasive potentials of carcinomas greatly contribute to their metastasis, which is a major threat in most cancers. We have recently shown that Arf6 plays a pivotal role in breast cancer invasive activities and identified AMAP1 as an effector of GTP-Arf6 in invasion. Expression of AMAP1 correlates well with invasive phenotypes of primary tumors of the human breast. We also have shown that AMAP1 functions by forming a trimeric protein complex with cortactin and paxillin. In this complex, AMAP1 binds to the src homology 3 (SH3) domain of cortactin via its proline-rich peptide, SKKRPPPPPPGHKRT. SH3 domains are known to bind generally to the proline-rich ligands with a one-to-one stoichiometry. We found that AMAP1/cortactin binding is very atypical in its stoichiometry and interface structure, in which one AMAP1 proline-rich peptide binds to two cortactin SH3 domains simultaneously. We made a cell-permeable peptide derived from the AMAP1 peptide, and we show that this peptide specifically blocks AMAP1/cortactin binding, but not other canonical SH3/proline bindings, and effectively inhibits breast cancer invasion and metastasis. Moreover, this peptide was found to block invasion of other types of cancers, such as glioblastomas and lung carcinomas. We also found that a small-molecule compound, UCS15A, which was previously judged as a weak inhibitor against canonical SH3/proline bindings, effectively inhibits AMAP1/cortactin binding and breast cancer invasion and metastasis. Together with fine structural analysis, we propose that the AMAP1/cortactin complex, which is not detected in normal mammary epithelial cells, is an excellent drug target for cancer therapeutics.


    Organizational Affiliation

    Department of Molecular Biology, Osaka Bioscience Institute, Osaka 565-0874, Japan.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
cortactin isoform a
A, B, C, D
66Homo sapiensMutation(s): 0 
Gene Names: CTTN (EMS1)
Find proteins for Q14247 (Homo sapiens)
Go to Gene View: CTTN
Go to UniProtKB:  Q14247
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
proline rich region from development and differentiation enhancing factor 1
P, Q
15Homo sapiensMutation(s): 0 
Gene Names: ASAP1 (DDEF1, KIAA1249)
Find proteins for Q9ULH1 (Homo sapiens)
Go to Gene View: ASAP1
Go to UniProtKB:  Q9ULH1
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
SO4
Query on SO4

Download SDF File 
Download CCD File 
P, Q
SULFATE ION
O4 S
QAOWNCQODCNURD-UHFFFAOYSA-L
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.9 Å
  • R-Value Free: 0.226 
  • R-Value Work: 0.216 
  • Space Group: C 2 2 21
Unit Cell:
Length (Å)Angle (°)
a = 71.450α = 90.00
b = 132.140β = 90.00
c = 61.200γ = 90.00
Software Package:
Software NamePurpose
CCP4data scaling
CNSrefinement
MOSFLMdata reduction
MOLREPphasing

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2006-04-25
    Type: Initial release
  • Version 1.1: 2008-04-30
    Type: Version format compliance
  • Version 1.2: 2011-07-13
    Type: Version format compliance